HER2 test results can vary in up to 10% of patients when multiple tumor blocks are analyzed, according to Mayo Clinic researchers. This variability has significant implications for patient treatment and highlights the need for additional testing.
The ASCB's annual film and image contest, Celldance, recognizes 10 members for their visually engaging and scientifically important videos and images. The winning videos and images will be shown on Saturday, Dec. 11, at the ASCB's 50th annual meeting in Philadelphia.
Researchers found that a depression drug, duloxetine, reduced joint and muscle pain in women taking aromatase inhibitors for breast cancer treatment by at least 30%. The study suggests that duloxetine may be an effective treatment option for this type of pain, with only mild additional side effects.
Researchers developed a new imaging technique that uses single photon emission computed tomography (SPECT) with computerized tomography (CT) scans to pinpoint critical lymph nodes under the arm. This allows physicians to block these nodes from X-ray beams, reducing radiation and subsequent lymphedema in breast cancer patients.
A higher prescription co-payment is associated with early discontinuation and incomplete use of adjuvant aromatase inhibitor therapy in hormone-sensitive early stage breast cancer. Women over 50 years old are more likely to discontinue medication or not take it as prescribed if co-payments exceed $30.
Researchers identified significant effects of different treatment options on infant outcomes, including higher rates of congenital malformations in premature deliveries. The study suggests that pregnant women with breast cancer should continue their pregnancy and receive standard treatment recommendations.
A study found that higher co-payments increase the chance of early discontinuation and inadequate use of breast cancer therapy, particularly among older women. Co-payments above $90 were associated with a higher risk of discontinuation in both younger and older age groups.